The aim of this study was to determine the effect of RNA interference inhibition of mineralocorticoid receptor (MR) on cold-induced hypertension (CIH) and renal damage. Recombinant adeno-associated virus (AAV) carrying short hairpin small interference (si)RNA for MR (AAV.MR-shRNA) was constructed and tested for the ability to inhibit renal MR and to control CIH. Three groups of rats with CIH received AAV.MR-shRNA (1.25 Â 10 9 particles/rat, intravenous), AAV carrying scrambled shRNA (AAV.Control-shRNA) (1.25 Â 10 9 particles/rat, intravenous) and phosphate buffer solution (PBS), respectively. All rats were kept in a cold chamber (6.71C) throughout the experiment. Adeno-associated virus delivery of MR-shRNA prevented progression of CIH. Blood pressure (BP) of the AAV.MR-shRNA-treated group did not increase and remained at 14573 mm Hg, whereas BP of the AAV.Control-shRNA-treated and PBStreated group increased to 16774 and 16173 mm Hg, respectively, at 3 weeks after gene delivery. Thus, the antihypertensive effect of a single injection of AAV.MRshRNA lasted for at least 3 weeks (length of the study). Adeno-associated virus carrying short hairpin siRNA for MR significantly increased urinary sodium excretion and decreased proteinuria. It also decreased serum creatinine and blood urea nitrogen, suggesting enhanced renal function. Both Western blot and immunohistochemical analysis showed that MR expression was decreased significantly in the kidney in the AAV.MR-shRNA-treated rats, confirming that renal MR is effectively inhibited by AAV.MR-shRNA. Adeno-associated virus carrying short hairpin siRNA for MR also significantly attenuated renal hypertrophy. In addition, AAV delivery of MR-shRNA prevented atrophy and dilation of renal tubules and abolished tubular deposition of proteinaceous material seen in CIH rats. Conclusions: (1) AAV delivery of MR-shRNA effectively silenced MR in vivo. (2) RNA interference inhibition of MR may open a new avenue for the long-term control of hypertension and renal damage.
Introduction
The renin-angiotensin-aldosterone system (RAAS) is an endocrine system that plays an important role in the regulation of blood pressure (BP). The overactivity of the RAAS is involved in the pathogenesis of hypertension, including cold-induced hypertension (CIH). As a key component of the RAAS, mineralocorticoid receptor (MR) is an attractive target for therapeutic intervention for hypertension and end organ damage.
1,2 Indeed, MR antagonists prevented left ventricular inflammation and fibrosis, 3, 4 stiffening of the carotid artery, 5 endothelial dysfunction and activation of nicotinamide adenine dinucleotide phosphate oxidase 6, 7 in aldosterone-infused rats. Eplerenone prevented the BP increase in response to salt loading and attenuated cardiac and vascular remodeling in stroke-prone spontaneously hypertensive rat (SHRSP) rats. 8 In contrast, the effect of MR antagonism on renal damage is poorly studied.
Although pharmacological MR blockers such as spironolactone are used for the treatment of hypertension, they interact with androgen and progesterone receptors and therefore cause sex-stereoid-like effects, including gynecomastia and breast pain. The new pharmacological MR antagonist, eplerenone, was designed to competitively antagonize aldosterone binding to MR based on a similar structure. However, eplerenone was found to increase serum triglycerides, cholesterol, alanine aminotransferase, gamma glutamyl transpeptidase, creatinine and uric acid in a dose-dependent manner. 9 These side effects may cause poor tolerance. In addition, these drugs are short lasting and therefore, daily doses are needed. Clearly, specific and long-term knockdown of MR is needed for better control of hypertension and end organ damage. RNA interference (RNAi) is aimed at inhibiting gene expression at the RNA level using small interference RNA (siRNA) or short hairpin siRNA (shRNA, double strands ligated with a loop sequence). RNA interference can mediate effective and sequence-selective suppression of a target gene expression. Adeno-associated virus (AAV) is a non-pathogenic and non-inflammatory vector. Therefore, in the present study, we constructed the recombinant AAV carrying shRNA for MR (AAV.MR-shRNA) and tested the effect of AAV.MR-shRNA on CIH and renal damage.
People who live in the cold areas have a high incidence of hypertension and related cardiovascular diseases. [10] [11] [12] [13] [14] [15] [16] Of the four seasons, cold winter has the highest mortality and morbidity of cardiovascular diseases in a year. [15] [16] [17] [18] Cold temperatures make hypertension more severe in hypertensive patients. 10, 14, 15, [19] [20] [21] Chronic cold exposure induces hypertension and cardiac hypertrophy in rats within 1-3 weeks, 22, 27, 31, 32 namely CIH. Cold-induced hypertension is a natural form of experimentally induced hypertension that does not require surgery, administration of large doses of hormones or drugs, or genetic manipulation. 22, 23 The characteristics of CIH are similar to those of human essential hypertension. [22] [23] [24] Cold-induced hypertension model was chosen for in vivo test because CIH is associated with the overactivity of the RAAS. [25] [26] [27] [28] [29] We hypothesized that AAV delivery of MR-shRNA attenuates CIH and renal damage.
Materials and methods

Construction of recombinant adeno-associated virus with mineralocorticoid receptor-shRNA
Three MR-shRNAs were designed using DHARMA-CON's software and synthesized by IDT DNA (Coralvill, IA, USA). We tested the inhibitory effect of the three MRshRNAs on MR expression in Ypen-1 prostate cancer cells. Only one MR-shRNA that achieved the greatest MR inhibition was chosen for the in vivo test. The sense and antisense sequence of the chosen MR and the short hairpin are given in Figure 1a . These sequences were designed to target on rat MR at CCAACAAGGAA GCCTGAGC (position in gene sequence: nucleotide 842-860). Adeno-associated virus-2 (Stratagene, La Jolla, CA, USA) was chosen as a vector because of its high affinity to renal tubule epithelial cells. Adeno-associated virus U6-MR-shRNA plasmid was constructed as illustrated in Figure 1b . Mineralocorticoid receptor-shRNA was driven by human RNA polymerase III U6 promoter. Adeno-associated virus U6-MR-shRNA was then packaged with pHelper and pAAV-RC to produce recombinant AAV.MR-shRNA. The titer was determined by real-time PCR as described by Rohr. 30 Adeno-associated virus with scrambled shRNA was also constructed to serve as a control (AAV.Control-shRNA). The scrambled shRNA has been tested by BD Clontech (Palo Alto, CA, USA) not to match with any known gene sequences.
Animal study protocols
This study was carried out according to the guidelines of the National Institute of Health on the care and use of laboratory animals. The project, of which this study was a part, was approved by the Institutional Animal Care and Use Committee.
We used three groups of Sprague-Dawley rats (180-200 g, six rats/group) that had developed CIH (BP4140 mm Hg) after 5 weeks of exposure to moderate cold (6.71C). All animals were kept in a cold climatecontrolled walk-in chamber (6.7721C) throughout the experiment. All rats were housed individually and provided with Purina laboratory chow (#5001) and tap water ad libitum. Blood pressure and body weight (b.w.) were measured three times during a 1-week control period. Resting systolic BP was measured at room temperature from the tail of each unanesthetized rat using the tail-cuff method with slight warming (281C), but not heating of the tail. All rats were handled frequently (two times/day) to minimize handling stress. Animals did not appear stressed during BP measurement. The tail-cuff method is a common method used by Sun et al., [27] [28] [29] Wang et al., 31, 32 Peng et al. 33 and Zhu et al.
34
to delineate CIH. It has been confirmed by the intraarterial cannulation that the non-invasive tail-cuff method is effective and reliable in monitoring systolic BP in rats exposed to cold. 24, 35 Following the 1-week control period, the three groups of rats received AAV.MR-shRNA, AAV carrying scrambled shRNA (AAV.Control-shRNA) and phosphate buffer solution (PBS), respectively. Adeno-associated virus carrying short hairpin siRNA for MR (1.25 Â 10 9 particles/rat, 0.5 ml), AAV.Control-shRNA (1.25 Â 10 9 particles/rat, 0.5 ml) and PBS (0.5 ml) were administered intravenously (intravenous, jugular vein) under anesthesia (sodium pentobarbital, 65 mg/kg).
Blood pressure and b.w. were measured every 4 days after intravenous gene delivery. A 24-h food intake, water intake and urine output were measured during week 3 of treatment. Urine was saved for measuring urinary Na + output by flame photometry as described in our previous studies. 28 Urinary albumin concentration was measured using the Nephrat Albumin enzymelinked immunosorbent assay kit (Exocell, Philadelphia, PA, USA). 36 At the end of week 3, all animals were perfused transcardially with heparinized saline under deep anesthesia with sodium pentobarbital (100 mg/kg, intraperitoneal). Before perfusion, blood was collected for measuring blood urea nitrogen (BUN) and creatinine. Blood urea nitrogen was determined by Alfa Wassermann's VetACE biochemistry analyzer (Alfa Wassermann, West Caldwell, NJ, USA). Serum creatinine was measured using a creatinine analyzer (Beckman Instruments, Inc., 
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Brea, CA, USA). Kidneys were removed and weighed. The right kidneys, heart and aortas were saved for quantification of MR expression using Western blot analysis. The left kidney was fixed in 4% paraformaldehyde overnight for localizing changes in MR expression using immunohistochemical analysis.
Western blot analysis of mineralocorticoid receptor, glucocorticoid receptor and androgen receptor expression in the kidney cortex, heart and aorta
Western blot analysis was performed as described previously. 29, 31 Briefly, membrane was blocked with 5% fat-free milk for 60 min, then incubated with mouse anti-MR primary antibody (1:750, Affinity BioReagents Inc., Golden, Co), rabbit anti-glucocorticoid receptor (GR) primary antibody (1:1000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or rabbit anti-androgen receptor (AR) primary antibody (1:500, Santa Cruz). Goat anti-mouse or goat-anti-rabbit with horseradish peroxidase (1:2000, Santa Cruz) was used as a secondary antibody and incubated for 1 h. Glyceraldehyde-3-phosphate dehydrogenase protein expression was measured and served as an internal control. Protein band density was quantified using gel doc system (BioRad, Hercules, CA, USA).
Immunohistochemical analysis of mineralocorticoid receptor expression and histological examination of kidneys
The immunohistochemical procedure has been described in our previous study. 31 Briefly, the kidneys were fixed with 4% paraformaldehyde in PBS at 41C overnight followed by 70% ethanol at 41C overnight, and then embedded with paraffin wax. Tissue sections were cut at 5 mm. Some sections were processed for immunohistochemical analysis of MR expression using mouse anti-MR primary antibody (1:500, Affinity BioReagents Inc., Golden, Co). The remaining tissue sections were used for histological examination using hematoxylin and eosin staining. Staining was visualized with horseradish peroxidase system (Dako Corporation, Carpinteria, CA, USA). Digital photographs were taken using a Zeiss microscope and imaging software (SPOT).
Statistical analysis
The data for BP and b.w. were analyzed by a two-way analysis of variance (ANOVA) (temperature and treatment) for repeated measurements (in time). The data for kidney weight, sodium output, proteinuria and MR protein expression were analyzed by a two-way ANOVA (temperature and treatment). The Neman-Keuls procedure was used to assess the significance of difference between means. The significance was set at 95% confidence limit.
Results
Effects of adeno-associated virus carrying short hairpin small interference RNA for mineralocorticoid receptor on cold-induced hypertension and kidney weight After 5 weeks of exposure to cold, resting systolic BP of all four groups was above 140 mm Hg (Figure 2 ). Blood pressure did not differ between any two groups before the gene delivery. Blood pressure of the PBS-treated group continued to increase (Po0.01) and stabilized at 16173 mm Hg at 3 weeks after injection. In contrast, BP of the AAV.MR-shRNA-treated group did not increase significantly (P40.05) compared with its pretreatment level. The BP of this group was 14573 mm Hg at 3 weeks after gene delivery. Thus, AAV.MR-shRNA prevented further BP rise. Blood pressure of the AAV.ControlshRNA-treated group increased significantly (Po0.01) and reached a level of 16774 mm Hg by 3 weeks. There was no significant difference (P40.05) in BP between the AAV.Control-shRNA-treated group and PBS-treated group, indicating that AAV vector or scrambled shRNA did not affect BP. Figure 3 Effects of adeno-associated virus carrying short hairpin small interference (si)RNA for mineralocorticoid receptor (MR) (AAV.MR-shRNA) on kidney weight (means7s.e.). This was measured when animals were killed at 3 weeks after gene delivery. ***Po0.001 compared with the adeno-associated virus carrying scrambled shRNA-treated group; +++ Po0.001 compared with the AAV.MR-shRNA-treated group. The normal range of kidney weight of rats kept at room temperature is 0.6-0.65 g/100 g body weight (b.w.), n ¼ 6.
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Kidney weight of the AAV.MR-shRNA-treated group was decreased significantly (Po0.001) compared with that of the AAV.Control-shRNA-treated group or PBStreated group (Figure 3) . Thus, AAV delivery of MRshRNA attenuated renal hypertrophy in CIH rats. There was no significant difference (P40.05) in kidney weight between the AAV.Control-shRNA-treated group and PBS-treated group, indicating that AAV or scrambled shRNA did not affect renal hypertrophy.
Body weight, food intake, water intake and urine output Body weight did not differ significantly (P40.05) among the three groups throughout the experiment. Body weight was 351714, 34679 and 358713 g for AAV.MR-shRNA group, AAV.Control-shRNA group and PBS group, respectively. Food intake, water intake and urine output were not significantly different (P40.05) among the three groups (data not shown), indicating that gene delivery did not affect these parameters.
Effects of adeno-associated virus carrying short hairpin small interference RNA for mineralocorticoid receptor on urinary sodium output and albuminuria Adeno-associated virus carrying short hairpin siRNA for MR significantly increased (Po0.001) urinary sodium excretion compared with the AAV.Control-shRNAtreated or the PBS-treated group (Figure 4a) . No significant difference of sodium excretion was found between the AAV.Control-shRNA-treated and PBS-treated groups.
Adeno-associated virus carrying short hairpin siRNA for MR significantly decreased (Po0.001) urinary albumin level compared with the AAV.Control-shRNAtreated or the PBS-treated group (Figure 4b) . No significant difference of albuminuria was found between the PBS-treated and the AAV.Control-shRNA-treated groups.
Effects of adeno-associated virus carrying short hairpin small interference RNA for mineralocorticoid receptor on serum creatinine and blood urea nitrogen Effects of adeno-associated virus carrying short hairpin small interference (si)RNA for mineralocorticoid receptor (MR) (AAV.MR-shRNA) on urinary sodium output (means7s.e.) (a) and albuminuria (means7s.e.) (b). This was measured during week 3 after gene delivery. **Po0.01, ***Po0.001 compared with the adeno-associated virus carrying scrambled shRNA-treated group; ++ Po0.01,
+++
Po0.001 compared with the AAV.MR-shRNA-treated group. The normal range of urinary sodium output is about 6-10 mequiv./b.w./day for rats kept at room temperature and is 12-18 mequiv./b.w./day for rats exposed to cold, due to which the food intake is doubled in cold-exposed rats. 28 The normal range of urinary albumin output of rats kept at room temperature is about 14-16 mg/day, n ¼ 6. that AAV delivery of MR-shRNA did not inhibit MR expression in heart and aorta. Renal GR and AR expression was not significantly (P40.05) different between any two groups (data not shown), indicating that AAV.MR-shRNA did not affect GR and AR.
Immunohistochemical analysis of mineralocorticoid receptor expression
Strong MR expression (heavy brown staining) was found in the renal tubule epithelial cells in the PBS-treated and AAV.Control-shRNA-treated rats (Figure 7) . Mineralocorticoid receptor was localized in the cytoplasma and nucleus, showing correct subcellular localization of MR. Mineralocorticoid receptor staining was greatly decreased in the AAV.MR-shRNA-treated rats, indicating effective inhibition of MR expression. Mineralocorticoid receptor expression was not found in glomerular vascular cells in rats receiving any treatment (Figure 7 ).
Histological examination of kidney
Some renal cortical tubules were atrophic, dilated and filled with proteinaceous material in both PBS-and AAV.Control-shRNA-treated rats (Figure 8 ). However, these pathological changes disappeared in the AAV.MRshRNA-treated rats, indicating that RNAi inhibition of MR abolished cold-induced renal damage.
Discussion
The present study clearly showed that AAV delivery of MR-shRNA prevented progression of CIH. Mineralocorticoid receptor was effectively inhibited, as evidenced by the decreased MR protein expression and the suppressed MR function (increased sodium excretion) in the AAV.MR-shRNA-treated rats. It is notable that a single dose of AAV.MR-shRNA suppressed renal MR and controlled CIH for upto 3 weeks (length of the study). In contrast, the half-life of eplerenone, a new MR antagonist, is less than 12 h 9 and daily doses are required. 37 In addition, MR-shRNA was designed to specifically inhibit MR based on the mRNA sequence and does not interact with any other known gene sequences according to the blast results. Indeed, AAV.MR-shRNA did not affect GR or AR expression, confirming the specificity of MR-shRNA. Therefore, RNAi knockdown of MR may offer an ideal approach for long-term control of hypertension. The antihyperten- MR-shRNA on CIH X Wang et al sive effect of AAV.MR-shRNA may be partially owing to the increased urinary sodium excretion by inhibition of MR in the kidney. Importantly, RNAi knockdown of MR significantly attenuated renal hypertrophy. It is even more interesting that AAV delivery of MR-shRNA abolished tubular atrophy and dilation and tubular deposition of proteinaceous material, the signs of the end-stage kidney. Moreover, RNAi inhibition of MR attenuated renal damage, as evidenced by a significant reduction of albuminuria in rats treated with AAV.MRshRNA. These results suggest that AAV delivery of MRshRNA may provide a novel approach for prolonged and effective renoprotection.
Our previous studies showed that cold-induced renal hypertrophy is independent of pressure overload because prevention or a reduction of CIH does not attenuate the cold-induced increase in kidney weight. 28, 38 The present study indicates that the renoprotective effect of AAV.MR-shRNA was likely due to inhibition of renal MR rather than attenuation of CIH because MR inhibition did not decrease blood pressure below pre-treatment level. Indeed, MR is involved in the pathogenesis of renal hypertrophy. 39 Physiologically, small-molecule proteins such as albumin are re-absorbed in tubular epithelial cells via endocytosis. Adeno-associated virus carrying short hairpin siRNA for MR attenuated albuminuria and abolished tubular deposition of proteinaceous material, suggesting that RNAi inhibition of MR may ameliorate the tubular function in re-absorbing albumin. Indeed, RNAi inhibition of MR enhanced renal function, as evidenced by decreased BUN and serum creatinine in AAV.MR-shRNA-treated rats. The immunohistochemical analysis revealed that the antibody staining was localized in the cytoplasm and nuclei of tubule epithelial cells, which matches the subcellular localization of MR. Western blot analysis using the same antibody further showed that MR protein expression was decreased by specific inhibition of MR using AAV.MR-shRNA. Therefore, these results confirmed that the anti-MR antibody used is specific for MR and is reliable for detecting MR.
Adeno-associated virus was chosen to carry MR shRNA because AAV is safe, non-pathogenic, noninflammatory and extremely stable. 40, 41 Nevertheless, a virus control (AAV.Control-shRNA) and a virus-free control (PBS) were used to exclude possibilities that may complicate interpretation of the experimental data due to the employment of viral vector. Control-shRNA is scrambled in sequence and has been proven, by BD Clontech (Palo Alto, CA, USA), not to interact with any known gene sequence. No signs of inflammation were seen during autopsy and no viral effect was observed in data analysis. It is known that the AAV vector can deliver target genes to the nuclei of cells, where the target gene then integrates into the host genome. 40, 42 These features make it possible to develop permanent gene therapy for humans using AAV vector. In the present study, we employed AAV-2, which has a high selective affinity, to renal tubule epithelial cells. 43 Indeed, AAV.MR-shRNA effectively inhibited MR in the kidney, but did not affect MR expression in the heart and aorta. Further studies are required to determine if the U6 promoter used in this study has high selectivity to the kidney. Thus, AAV.U6 may be an effective vector complex for delivering therapeutic genes to the kidney.
In summary, blockade of MR has been shown to have an antihypertensive effect and an organ protection effect. However, the use of pharmacological MR antagonists is limited because of side effects incurred by their interaction with glucocorticoid and ARs. Moreover, these drugs are short lasting (o1 day). The present study showed that AAV delivery of MR-shRNA effectively silenced MR expression and prevented progression of CIH. A single dose of AAV.MR-shRNA controlled CIH for upto 21 days (length of the study). Importantly, RNAi inhibition of MR also offered prolonged renoprotection. Therefore, RNAi knockdown of MR may open a new avenue for long-term and effective control of hypertension and renal damage.
